Nova Safo

Joseph Gagnon is with the Peterson Institute for International Economics.

And that could happen if there's massive or long-term damage to oil production facilities in the Middle East.

Inflation is another story.

The OECD forecasts a boost to 4% on average among the world's biggest economies from higher energy prices.

Ben May of Oxford Economics says the risk is that those price increases spread elsewhere.

Most central banks are likely to worry about that risk first, says Neil Shearing of Capital Economics.

As in, we'll expect more of it and create a self-fulfilling loop.

The key ingredient in all of this, analysts say, is time.

Can the Iran war end soon enough to avoid worse economic damage here and abroad?

I'm Novosafo for Marketplace.

Many companies have been reluctant to include GLP-1 weight loss drugs in their health benefits.

For one, they cost a lot, and a lot of people want to take them.

Matthew Ray, with a nonpartisan health policy research firm KFF, has been surveying companies about the issue and says that those that do pay for the drugs have found themselves in a pickle.

That's led to a serious math problem, says Luca Maini of Harvard Medical School.

Some companies have even dropped coverage of them altogether.

Overall, only one in five employer-sponsored health plans cover the drugs for weight loss.

Eli Lilly has announced a new initiative trying to address these problems.

Senior Vice President Kevin Hearn says they're offering one transparent price, $450 a month for ZepBound, so that companies can budget better.

Eli Lilly is also partnering with telehealth providers to help companies administer the drugs.

In order to get more of them to conclude that paying for the drugs is cheaper in the long run than the costs associated with obesity.